Cargando…
Do proton pump inhibitors increase mortality? A systematic review and in‐depth analysis of the evidence
Proton pump inhibitors (PPIs) were primarily approved for short‐term use (2 to 8 weeks). However, PPI use continues to expand. Widely believed to be safe, we reviewed emerging evidence on increased mortality with PPI long‐term use. Our 2016 systematic PPI drug class review found that mortality was n...
Autores principales: | Ben‐Eltriki, Mohamed, Green, Carolyn J., Maclure, Malcolm, Musini, Vijaya, Bassett, Ken L., Wright, James M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525804/ https://www.ncbi.nlm.nih.gov/pubmed/32996701 http://dx.doi.org/10.1002/prp2.651 |
Ejemplares similares
-
Comparison of cholinesterase inhibitor safety in real-world practice
por: Carney, Greg, et al.
Publicado: (2019) -
Deprescribing proton pump inhibitors
por: Teh, Kim Jun Kevin, et al.
Publicado: (2023) -
Do Proton Pump Inhibitors Decrease Calcium Absorption?
por: Hansen, Karen E, et al.
Publicado: (2010) -
Factors Affecting Blood Pressure Variability: Lessons Learned from Two Systematic Reviews of Randomized Controlled Trials
por: Musini, Vijaya M., et al.
Publicado: (2009) -
Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data
por: Erviti, Juan, et al.
Publicado: (2022)